Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821177) titled 'Bladder Preservation or Cystectomy for MIBC' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Dana-Farber Cancer Institute
Condition:
Muscle-Invasive Bladder Carcinoma
Bladder Cancer
Urothelial Carcinoma
Intervention:
Drug: Gemzar
Drug: Cisplatin
Drug: Adrucil
Drug: Mitomycin
Recruitment Status: Not recruiting
Phase: Early Phase 1
Date of First Enrollment: September 2, 2026
Target Sample Size: 20
Countries of Recruitment:
United States
To know more, visit h...